SOX2 and colorectal carcinoma: In line with these findings, it has been shown that SOX2 is involved in mesenchymal–epithelial-transition (MET), the reversion of EMT; a knockdown of SOX2 in colorectal cancer (CRC) cells altered the expression of key genes involved in the EMT process, including E-cadherin and Vimentin [40].